Overview

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Status:
Active, not recruiting

Trial end date:
2023-05-17

Target enrollment:

Participant gender:

Summary

This is a study of tirzepatide in participants with obesity or overweight. The main purpose is to learn more about how tirzepatide maintains body weight loss. The study has two phases: a lead-in phase in which all participants take tirzepatide and a treatment phase in which participants will either continue tirzepatide or switch to placebo. The study will last about 2 years (25 visits).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

LY3298176
Tirzepatide